Close Menu

GenMark

The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.

The GenomeWeb index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index.

The Carlsbad, California-based molecular diagnostics firms reported $18.4 million in revenues, up from 14.9 million in Q2 of 2018.

It placed 39 net new ePlex analyzers, expanding the global installed base to 393 placements and growing its installed base by 72 percent compared to the prior-year period.

The company has split bloodstream infection testing into three multiplex panels that can detect a total of 56 pathogen targets and 10 markers of antimicrobial resistance.

The test completes a suite of assays designed to detect pathogens that can cause sepsis using the firm's ePlex system.

Natera and Veracyte both received positive news regarding local coverage determinations from Medicare contractors, while the catalysts for Fluidigm's rise were unclear.

The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.

The firm used about $38.8 million on Feb. 1 to repay all outstanding principal, interest, related fees, and other obligations under an existing loan agreement.

Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.

Pages

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.